Enterprise Value

265M

Cash

111.2M

Avg Qtr Burn

-19.0M

Short % of Float

17.30%

Insider Ownership

0.41%

Institutional Own.

56.71%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VOWST (SER-109) Details
Bacterial infection, Clostridioides difficile infection

Approved

Quarterly sales

SER-155 Details
Intestinal infection, Graft-versus-host disease

Phase 1b

Data readout

SER-301 Details
Inflammatory bowel disease, Ulcerative colitis

Failed

Discontinued

SER-287 Details
Inflammatory bowel disease, Ulcerative colitis

Failed

Discontinued

SER-401 Details
Melanoma, Cancer

Failed

Discontinued